Suppr超能文献

仅因切缘阳性而处于 Wilms 肿瘤 III 期的患者的预后:英国-CCLG 和 GPOH 研究中按照 SIOP-WT-2001 方案治疗的患者的分析。

Outcomes of patients with Wilms' tumour stage III due to positive resection margins only: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies.

机构信息

Department of Pathology, Sidra Medicine, Doha, Qatar.

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine - Qatar, Doha, Qatar.

出版信息

Int J Cancer. 2023 Apr 15;152(8):1640-1647. doi: 10.1002/ijc.34371. Epub 2022 Nov 30.

Abstract

Stage III Wilms' tumour (WT) represents a heterogeneous group which includes different criteria, but all stage III patients are treated according to the same study regiment. The aim of the study was to retrospectively analyse outcomes in patients with stage III due to positive resection margins (RM) only, sub-grouped in RM with viable (RM-v) and nonviable (RM-nv) tumour. Patients were treated pre- and postoperatively according to the SIOP-WT-2001 protocol in the UK-CCLG and GPOH WT trials and studies (2001-2020). There were 197 patients, including 134 with localised, abdominal stage III and 63 with overall stage IV, but abdominal stage III. Stage III due to RM-v had 126 patients, and due to RM-nv 71 patients. The overall 5-year local-relapse-free survival (RFS), event-free (EFS) and overall survival (OS) estimates for all patients with abdominal stage III RM were 95.7% (±SE1.5%), 85.1 (±SE2.6%) and 90.3% (±SE2.2%), respectively. Patients with stage III RM-nv had significantly better RFS and EFS than patients with RM-v (P = .027 and P = .003, respectively). A multivariate analysis showed that RM-v remained a significant factor for EFS when adjusted for age, presence of metastasis at diagnosis, histological risk group and overall stage in Cox regression analysis (P = .006). Patients with stage III due to RM-nv only exhibited no local recurrence and have a significantly better RFS and EFS than patients with RM-v. The results suggest that exclusion of RM-nv as a stage III criterion in the UMBRELLA staging system and consequent treatment reduction is warranted.

摘要

III 期肾母细胞瘤 (WT) 代表了一组异质性的患者群体,其中包括不同的标准,但所有 III 期患者都按照相同的研究方案进行治疗。本研究的目的是回顾性分析仅因切缘阳性 (RM) 而处于 III 期的患者的结局,这些患者进一步分为 RM 中有活力 (RM-v) 和无活力 (RM-nv) 肿瘤的亚组。患者在英国-CCLG 和 GPOH WT 试验和研究 (2001-2020 年) 中按照 SIOP-WT-2001 方案进行术前和术后治疗。共有 197 例患者,其中 134 例为局限性、腹部 III 期,63 例为整体 IV 期,但为腹部 III 期。由于 RM-v 而处于 III 期的患者有 126 例,由于 RM-nv 而处于 III 期的患者有 71 例。所有腹部 III 期 RM 患者的总体 5 年局部无复发生存率 (RFS)、无事件生存 (EFS) 和总生存率 (OS) 估计值分别为 95.7%(±SE1.5%)、85.1%(±SE2.6%)和 90.3%(±SE2.2%)。RM-nv 患者的 RFS 和 EFS 显著优于 RM-v 患者(P=.027 和 P=.003)。多变量分析显示,在校正 Cox 回归分析中的年龄、诊断时转移的存在、组织学风险组和整体分期后,RM-v 仍然是 EFS 的一个显著因素(P=.006)。仅因 RM-nv 而处于 III 期的患者没有局部复发,并且 RFS 和 EFS 显著优于 RM-v 患者。结果表明,在 UMBRELLA 分期系统中排除 RM-nv 作为 III 期标准,并相应减少治疗是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验